Dr. Surender Khurana is a scientist at the US Food and Drug Administration (FDA). He embarked on his journey of scientific research with a doctorate in biochemistry wherein he studied the diverse molecular mechanisms of antibody immune response generated following HIV infection. As a post-doctoral fellow at FDA, he developed the first differential serodiagnostic assay for true HIV infections in-face of HIV vaccine clinical trials (the HIV-SELECTEST) to address the issue of vaccine-induced seropositivity (VISP). In 2007, Dr. Khurana joined as staff scientist in the Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA.
Dr. Khurana’s scientific interests are understanding how viral infection, different vaccine modalities, and novel adjuvants impact immunity against viral pathogens. He developed novel scientific technologies of whole genome phage display libraries for antibody epitope repertoires and measuring antibody affinity maturation in polyclonal human samples using surface plasmon resonance following vaccination or infection. These findings have provided new insights for knowledge-based design of potency assays, serodiagnostic assays, and for development and evaluation of effective vaccines against influenza, respiratory syncytial virus (RSV), Zika, and Ebola.
Dr. Khurana has authored more than 70 publications in peer-reviewed scientific journals including Cell, Nature Medicine, Science Translational Medicine, PLoS Medicine, and PNAS. Dr. Khurana is part of several World Health Organization committees and international expert panels. He serves on the editorial boards of BioMed Research International and Vaccines.
Surender Khurana, PhD Presentations
- There were no results found.